Insights from 2023 ASCO® Annual Meeting

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Insights from 2023 ASCO® Annual Meeting

Breast
Hematology
Lung
GI
GU
GYN
Skin
Head and Neck
Sarcoma
CNS
Basic Science

Playback speed

10 seconds

ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"

By Insights from 2023 ASCO® Annual Meeting FEATURING Vivek Subbiah

1,235 views

July 6, 2023

Vivek Subbiah, MD, now Chief of Early-Phase Drug Development for Sarah Cannon Research Institute (SCRI), ...
read more ↘ discusses the research conducted at The University of Texas MD Anderson Cancer Center, Houston, TX.
↖ read less

Comments 0

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Lung